



innovotech

Corporate Presentation

Q1 2025

TSXV: IOT

Executive **Summary**

Innovotech is a Canadian microcap biotech company with deep client relationships, 20+ years of technical expertise, proprietary methods and intellectual property.

Our strategy is to build a diverse portfolio of revenue generating business lines while supporting targeted research for high value intellectual properties.

- Traded since 2004 on the **TSXV: IOT**
- **VWAP** C\$0.206
- **12-month high** C\$0.245
- **Market Cap** C\$9.45mm
- **49.7mm shares** outstanding
- Team of **36 Industry Professionals**




IOT Performance

Revenue growth driven by large contract research projects & acquisition of Keystone Labs in November 2024.

Strong balance sheet


- \$3.4mm assets
- No term debts



Market Opportunity

Growth Drivers

- Antimicrobial resistance is a growing concern with increasing pressure on medical device manufacturers for innovative solutions
- Biofilm science is still in its infancy and Innovotech has been a pioneer in this area
- Deep client relationships keep Innovotech at the forefront of evolving client needs
- Opportunities to develop products and new technologies that can scale more efficiently than services



¹[Microbiology CRO services market](#)

²[Antimicrobial Susceptibility Testing Market](#)

³[Translational challenges and opportunities in biofilm science: a BRIEF for the future](#)

IOT is organized into operating companies and business streams

Innovotech Inc.

Innovotech Labs Corporation

- Contract Research Services
- Production and sale of MBEC Assay® Kits
- InnovoSIL™ antimicrobial silver commercialization

Keystone Labs Corporation

- Analytical and microbiology services

NouLife Sciences Inc.


- R&D and Commercialization of antioxidant technologies

Stream 1: Microbiology-related Contract Research Services

- Innovotech is a leader in **contract research services**, focusing on microbial interactions with biosurfaces and antimicrobial effectiveness.
- Innovotech provides **research support** and **third-party testing**, as companies develop new coatings or products and plan to seek FDA-clearance for antimicrobial surface claims.
- Testing has been **successfully used for FDA 510(k) submissions**.

Expertise includes:


- Formation of biofilms on a variety of surfaces and testing under near-real world conditions
- Testing under aerobic, anaerobic, and microaerophilic conditions, and using bacterial and fungal strains
- Testing medical devices, as well as agricultural and oilfield products



Stream 2: MBEC Assay[®] Kits

Consumable Lab Supplies Required for Standard Antibiofilm Tests

- Typical purchasers are **industrial researchers, academia** and **governments**
- Basis for ASTM E2799 Method
- **Worldwide sales** direct from our webstore, innovotech.ca
- Innovotech retains **proprietary manufacturing methods**
- **MBEC Assay[®] Kits** come in different coatings for different use cases




Stream 2: MBEC Assay[®] Kits Shipped Globally



Stream 3: InnovoSIL™ -1 Antimicrobial silver commercialization

- New class of silver-iodine complexes
- Broad spectrum activity: shown to be effective against mature biofilms, superbugs and respiratory viruses, including COVID-19
- Slow-release properties allow for continuous release to prevent adherence to surfaces and eliminate surrounding microbes
- Multiple mechanisms of action; less likelihood of developing resistance
- **License -ready**, looking for commercialization partners
 - [Superbugs News Release](#)
 - [Viruses 2024 Article](#)



Untreated surface
after exposure to
Candida albicans



Surface treated with
Innovosil™-1 silver after
exposure to *Candida*
albicans

Stream 4: Analytical and Microbiology Services

Sterility & Micro



Ensure products meet the highest standards of microbial safety and cleanliness.

Environmental Monitoring



Manage the product environment and comply with regulations.

Method Development




Improve existing methods or create a new approach.

Analytical Chem



Analysis of pharmaceutical, biotechnology, medical device and nutraceutical.

Microbial Identification



Analyze the raw materials, active pharmaceutical ingredients and the finished products.

Stability Studies



Analysis of an active pharmaceutical ingredient (API) when exposed to different environmental factors.

Stream 5: NouLife Sciences Inc.

- Technology for advanced penetration of linked antioxidant molecules for diabetic neuropathy and cosmetic applications
- Successfully synthesized linked molecule with 3 linkers
- Completed stability studies
- Ongoing permeability studies
- Seeking commercialization partnerships
- Innovotech owns a 60% interest in IP-holding company, NouLife Sciences Inc.



IOT Outlook



Continuation of **contract research** projects through 2025



Expansion of contract research services offered from R&D – encrustation assays



Growth in **analytical chemistry** and **method development** projects enabled by an additional stability chamber and HPLC capacity adds long-term, recurring revenues




Developing **additional InnovoSIL™ silver family members** with unique properties



Commercialization of InnovoSIL™-1 silver


IOT R&D

Innovotech is continuing a focused program of R&D to expand the line of products and services in these key areas:



InnovoSIL™-1 Silver Development

- Further scale-up of manufacturing
- Determining compatibility with various processes/applications
- Further understanding unique mechanisms of action
- Optimizing coating processes
- Investigate more soluble forms of InnovoSIL™ Silver



Contract Research

- Development and validation of new customizable test methods
- Validation of anti-encrustation assays
- Development of clinically relevant methods simulating skin conditions



MBEC Assay® Kits

- Evaluating a new plate design developed at Duke University to improve in situ imaging and study of biofilm formations
- Developing additional surface treatments for improved MBEC Assay® Kits performance




NouLife Sciences

- Continuing work on the patented procedure for linked antioxidants


Quality & **Credibility**

- Accredited by CALA to ISO/IEC 17025 testing accreditation number A4146.
Enumerating Bacteria – solids.
Enumeration Bacteria – Liquids
- Keystone Labs is a Health Canada accredited GMP regulated facility with a Drug Establishment license
- Innovotech is recognized as the developer of the standard method ASTM E2799 and supplier of MBEC Assay® Kits



Quality & Credibility

- Innovotech developed the BEST Assay™ Method – an industry-leading approach used to study antimicrobial surface coatings on various medical devices
- Innovotech has generated data for clients that has been used by the FDA for product regulatory approvals
- Innovotech and its subsidiary Keystone have maintained long-standing client relationships – over 10 years



Board and Management



Craig Milne

MBA, Ph.D., CEO, Director

Entrepreneurial leader with proven track record of growing technology-enabled companies.



Tyler Boone

Ph.D., COO

Operations leader with PhD in microbiology. Leads client relations and contract research services.



Jodi McDonald

BSc., President, Keystone Labs

Entrepreneurial leader and quality assurance professional with strong track record of client driven outcomes.



Patricia Nadworny

Ph.D., P.Eng., CSO

Chemical & biomedical engineering leader with domain expertise in antimicrobial silver compounds, biofilms and medical devices.



Bernard Grobbelaar

CPA, CFO

CPA/CA with more than two decades of experience serving clients in the public, private, and not-for-profit sectors.



James Timourain

Ph.D., Board Chair

Entrepreneur, Investor, former mathematics professor.



Julie Wright

Director

Investor, marketing and public relations agency owner. California-based.



David Tam

Director

Corporate Lawyer with decades of experience in capital markets.



Karen Farkas

Director

Entrepreneur, former accounting professor.



Brad Clarke

CPA, CBV Director

Finance and operations professional for high growth, technology-enabled companies, M&A and tax strategies.

Cautionary Note Regarding Forward-Thinking Statements

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements.

Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers; fluctuations in operating results; government policies or actions; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company's exposure to lawsuits and other matters beyond the control of management.

Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.



Contact Us

Craig Milne

1-604-239-1819

craig.milne@innovotech.ca

Innovotech.ca

Corporate Presentation Q1-2025